ANDA Submission and GDUFA Guidance


Instructor: Charles H Paul
Product ID: 706791

  • Duration: 60 Min
An ANDA is an Abbreviated New Drug Application. This application is submitted to the FDA to seek approval to produce a U.S. generic drug from an existing patented approved drug. The ANDA is submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs. After approval, the applicant is able to produce and market the generic drug product.
Last Recorded Date: Mar-2022


1 Person Unlimited viewing for 6 month info Recorded Link and Ref. material will be available in My CO Section
(For multiple locations contact Customer Care)

Downloadable file is for usage in one location only. info Downloadable link along with the materials will be emailed within 2 business days
(For multiple locations contact Customer Care)



Customer Care

Fax: +1-650-362-2367

Email: [email protected]

Read Frequently Asked Questions

Why Should You Attend:

Anyone participating with the submittal process must understand how the process is structured and operated in order to bring generic pharmaceuticals and therapeutic products to market properly, successfully, and expeditiously. Furthermore, with the passing of GUFDA II, which drastically alters the fee structure, it is critical to comprehend the program's fundamental changes as well as their implications for the generics market.

Areas Covered in the Webinar:

  • Overview of the ANDA and PAS processes
  • Overview of GDUFA
  • The FDA’s process for classifying major, minor, and unsolicited amendments to ANDAs or PASs.
  • How ANDA or PAS deficiencies that will cause the FDA to request a major amendment or classify deficiency responses as a major amendment.
  • The amendment format and submission process.
  • The FDA's review goals for amendments under GDUFA II.
  • How the FDA will process amendments submitted before GDUFA II.
  • How to request that the FDA reconsider classifying a major amendment.
  • A discussion of how high quality standards are maintained through inspections and risk-based approaches.
  • The process of and reasons for requiring the identification of the facilities involved in the manufacture of generic drugs and the associated active pharmaceutical ingredients.
  • The intent of the FDA to expedite product access.
  • How amendment submissions may affect review goal dates.

Who Will Benefit:

The audience for this webinar would consist of anyone in the generic pharma business in the following functions:

  • Compliance and regulatory,
  • Research & development,
  • Quality assurance.
  • Positions would include – Director,
  • Associate Director,
  • Manager
  • Associates
Instructor Profile:
Charles H Paul

Charles H Paul
President, C H Paul Consulting Inc

Charles H. Paul is the President of C. H. Paul Consulting, Inc. – a regulatory, training, and technical documentation consulting firm. Charles is a management consultant, instructional designer and regulatory consultant and has led C. H. Paul Consulting, Inc. since its inception over 25 years ago. He regularly consults with Fortune 500 pharmaceutical, medical device, and biotechnology firms assisting them in achieving human resource, regulatory, and operational excellence. He is a regular presenter of webinars and on-site seminars in a variety of related subjects from documentation development to establishing compliant preventive maintenance systems. The firm works globally completing projects throughout the EU, UK, South America, and Asia.

Topic Background:

A generic drug product is equivalent to a patented drug product in terms of dosage, strength, route of administration, quality, performance characteristics and intended use. Generic drug applications are indicated as abbreviated because they are generally not required to include preclinical and clinical trials to establish safety and effectiveness. In place of clinical trials, generic applicants must demonstrate that their product is bioequivalent to the originally patented drug.

As part of this process, firms submitting ANDAs are required to submit user fees that are intended to improve the CDERs ability to perform their critical functions in this regard. The user fees were initially enacted under the Generic Drug User Fee Amendment in 2012 to help the FDA ensure that participants of the U.S. generic drug system comply with U.S. quality standards, and to increase the likelihood that American consumers will get timely access to low cost, high quality generic drugs.

In 2017, the FDA signed into law, the first reauthorization of the Generic Drug User Fee Amendments (GDUFA II). This reauthorization substantially alters the fee structure of this program. Recently the FDA finalized guidance to help review the goals established as part of this reauthorization as they apply to ANDAs and PASs (Prior Approval Supplements).

Together, the ANDA process and the Generic Drug User Fee Amendments Reauthorization of 2017 form the structure of our US generic medications process.

Follow us :



Refund Policy

Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).




6201 America Center Drive Suite 240, San Jose, CA 95002, USA

Follow Us

facebook twitter linkedin youtube


Copyright © 2023 MetricStream
Our Policies: Terms of use | Privacy

PAYMENT METHOD: 100% Secure Transaction

payment method